Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicul…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $34.85 | $8.48 | $12.95 |
| Estimado | $22.61 | $24.82 | $8.17 | $28.66 |
| Sorpresa | — | +40.4% | +3.8% | -54.8% |
| Métrica | GMAB.CO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 93.6% | 57.4% | +36.2% |
| Operating Margin | 28.6% | -34.4% | +63.0% |
| Net Margin | 25.9% | -32.5% | +58.3% |
| FCF Margin | 30.9% | -12.6% | +43.5% |
| ROE | 16.5% | -39.2% | +55.6% |
| ROA | 7.5% | -30.9% | +38.4% |
| Current Ratio | 2.02 | 2.73 | -0.71 |
| Debt / Equity | 0.86 | 0.28 | +0.58 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 7.5% | — |
| ✓Flujo de caja operativo positivo | $1.2B | $1.1B |
| ✗Rentabilidad sobre activos al alza | 7.5% | 17.7% |
| ✓Caja operativa/activos supera al ROA | 9.2% | ROA 7.5% |
| ✗Menos deuda a largo plazo | 38.8% | 0.0% |
| ✗Mejor liquidez (ratio corriente) | 2.02 | 5.24 |
| ✓Sin aumentar el nº de acciones | 63M | 65M |
| ✗Margen bruto al alza | 93.6% | 95.4% |
| ✗Rotación de activos al alza | 0.29 | 0.49 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 30.9% |
| ✗ROCE > 10 % | 9.3% |
| ✗Ventas > 5 %/año (3 años) | -36.5% |
| ✗Deuda neta/EBITDA < 3x | 3.1x |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 44.2% |
Riesgo de quiebra (Altman Z 3.1): zona segura
GENMAB A/S cotiza a 2502.00 DKK y tiene una capitalización bursátil de DKK 153.8B. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud